---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030374"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T10:03:21.132401+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Abeona raises $35M in private placement; Phase 3 EB-101 trial meets endpoints

## Summary
- Gross proceeds of $35M from sale of 7.07M shares, pre-funded warrants for 0.54M shares, and common warrants for 7.61M shares.
- Offering price per unit $4.60; common warrants exercisable at $4.75 per share for five years.
- Phase 3 VIITAL trial for EB-101 met co-primary, secondary, and exploratory endpoints with high statistical significance.
- Net proceeds plus existing resources expected to fund operations into Q3 2024.
- Placement includes new and existing investors: Adage Capital, Armistice Capital, Deerfield, EcoR1, Nantahala.

## SEC filing metadata
- accession: 0001493152-22-030374
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/0001493152-22-030374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030374
- JSON: https://secwatch.observer/filing/0001493152-22-030374.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030374.txt

## Key facts
- Material Agreements
  ABEONA THERAPEUTICS INC. entered into Securities Purchase Agreement with a group of investors (the “Purchasers”) valued at approximately $35.0 million (effective 2022-11-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a group of investors (the “Purchasers”)
  - Value: approximately $35.0 million
  - Effective: 2022-11-03
  source text: Abeona Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a group of investors (the “Purchasers”) providing for the private placement (the “Private Placement”) to the Purchasers of (i) 7,065,946 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) (ii) pre-funded warrants to purchase 543,933 shares of Common Stock with a term of five years from the issuance date (the “Pre-Funded Warrants”) and (iii) warrants to purchase 7,609,879 shares of Common Stock with a term of five years from the issuance date (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”), for an aggregate purchase price of approximately $35.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/0001493152-22-030374-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.